Rexahn Pharmaceuticals, Inc. Awarded Patent in Japan for Novel Anti-cancer Isoquinolinamine Compounds

Published: Jul 09, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that the Japan Patent Office has granted Patent No. 5270564 covering a series of novel isoquinolinamine compounds, their pharmaceutical composition, and method for producing an anti-tumor effect.

Help employers find you! Check out all the jobs and post your resume.

Back to news